Hematopoietic Stem-Cell Transplantation in the Developing World: Experience from a Center in Western India

Table 9

	Apollo Hospital International Limited, Gandhinagar; ( = 50)	Christian Medical College, Vellore; ( = 221) [7]	National Cancer Research Institute, Kolkata; ( = 22) [8]	Western studies
Bacterial infections	50%	34.9%	52%	5%
Viral infections	4%	42.9%	24%	7%
Fungal	14%	15.9%	12%	16%
Blood culture; positivity	22%	53.8%	50%	12.5% [9]
Incidence of gram negative infection	22%	80%	80%	11.2% [9]
Graft versus host; disease	Grade 1 skin GVHD in 6.7% (1/15), grade 2 skin GVHD in 6.7%, and acute hepatic GVHD grade 2-3; in 13.3% (2/15)	17% grade 3 and grade 4	Skin GVHD grade II in 18.2%, grade I GVHD of liver in 13.6%, and grades II-III gut GVHD in 9%	Data not available
Mortality rate	No mortality for the first month; 100 day mortality 8%; overall mortality 40% with the median follow-up of 39 months	Overall mortality is approximately 28%	Overall mortality was 13.7% at the median follow-up of 4.6 years	Mortality rate for allogeneic transplant is approximately 30% and for autologous transplant it is approximately 10% after 3 years of follow-up.(USA and Canada) [10]
Long term survival	Overall survival for thalassemia patients, autologous HSCT patients, and allogeneic HSCT patients was 66%, 65.7, and 57.1%, respectively, with median follow-up of 39 months	Overall survival 72.3 ± 3.1% of 218 patients of thalassemia at median follow-up of 5 years	Overall survival 86.3%; disease-free survival 68.2% seen at median follow-up of 22 patients for 4.6 years	50–70% in chronic leukaemias and 80–90% with aplastic anaemias (USA and Canada) [11]